

Preliminary Amendment
U.S. Patent Application No. 10/509,307

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) An agent for inhibiting phosphorylation of c-Jun, wherein the agent comprises one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 as active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

2. (original) The agent for inhibiting phosphorylation of c-Jun according to Claim 1, wherein the peptide group consists of (i), (ii), (iii), (iv), (x), and (xi).

3. (original) A method for inhibiting the phosphorylation of c-Jun, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3) in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting

Preliminary Amendment
U.S. Patent Application No. 10/509,307

the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

4. (original) The method for inhibiting the phosphorylation of c-Jun according to Claim 3, wherein the peptide group consists of (i), (ii), (iii), (iv), (x), or (xi).

5. (original) An agent for inhibiting the ability of c-Jun to activate transcription, wherein the agent comprises one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 as the active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

6. (original) A method for inhibiting the ability of c-Jun to activate transcription, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

7. (previously presented) A pharmaceutical composition comprising an effective dose of the agent for inhibiting the phosphorylation of c-Jun according to Claim 1.

8. (original) The pharmaceutical composition according to Claim 7, wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase 3.

9. (original) A pharmaceutical composition comprising an effective dose of one or more peptides selected from the following peptide group having a function for interacting with c-Jun

Preliminary Amendment
U.S. Patent Application No. 10/509,307

N-terminal kinase 3, wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in

Preliminary Amendment
U.S. Patent Application No. 10/509,307

Sequence List.

10. (original) A pharmaceutical composition comprising an effective dose of one or more polynucleotides encoding at least one peptide selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3), wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v),

Preliminary Amendment
U.S. Patent Application No. 10/509,307

wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

11. (original) The pharmaceutical composition according to Claim 8, wherein the disease caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase 3 is a neurodegenerative disease.

12. (original) The pharmaceutical composition according to Claim 11, wherein the neurodegenerative disease is polyglutamine disease, Huntington's disease, spinocerebellar ataxia, bulbosspinal muscular atrophy, dentatorubropallidoluysian atrophy, Alzheimer's disease, Down's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, familial British dementia, Creutzfeldt-Jakob disease, Gerstmann-Stranssler syndrome, mad cow disease (bovine spongiform encephalopathy) (BSE), or familial dementia accompanying neuroserpin inclusion bodies.

13. (original) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3) in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in

Preliminary Amendment
U.S. Patent Application No. 10/509,307

Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,

(vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having mutations of one to several acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

14. (original) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises utilizing one or more polynucleotides encoding at least one peptide selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3) to express the peptide encoded by

Preliminary Amendment
U.S. Patent Application No. 10/509,307

the polynucleotides, wherein the peptide inhibits the phosphorylation of c-Jun by JNK3:

- (i) BMAL1,
- (ii) BPL1,
- (iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
- (iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,
- (v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List,
- (vi) a peptide comprising at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (viii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (ix) a peptide having a homology of 70% or more to at least one peptide of said (i) to (v), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or
- (xi) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

Preliminary Amendment
U.S. Patent Application No. 10/509,307

15. (previously presented) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises using the pharmaceutical composition according to Claim 7.
16. (previously presented) The method for preventing and/or treating disease(s) according to Claim 13, wherein the disease caused by the phosphorylation of c-Jun by JNK3 is a neurodegenerative disease.
17. (original) The method for preventing and/or treating disease(s) according to Claim 16, wherein the neurodegenerative disease is polyglutamine disease, Huntington's disease, spinocerebellar ataxia, bulbospinal muscular atrophy, dentatorubropallidoluysian atrophy, Alzheimer's disease, Down's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, familial British dementia, Creutzfeldt-Jakob disease, Gerstmann-Strassler syndrome, mad cow disease (bovine spongiform encephalopathy) (BSE), or familial dementia accompanying neuroserpin inclusion bodies.
18. (original) At least one peptide selected from the following peptide group:
 - (i) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
 - (ii) a peptide comprising the peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
 - (iii) a peptide comprised of at least 5 consecutive amino acid residues in the amino acid sequence represented by SEQ ID NO: 1 in Sequence List, or
 - (iv) a peptide having mutations of one to several amino acids in at least one peptide of (i) to (iii).

Preliminary Amendment
U.S. Patent Application No. 10/509,307

19. (original) The peptide according to Claim 18, wherein the peptide has a function for interacting with c-Jun N-terminal kinase 3 (JNK3).
20. (previously presented) A polynucleotide comprising a nucleotide sequence encoding a peptide according to Claim 18, or a complementary sequence thereof.
21. (original) A polynucleotide comprised of a nucleotide represented by SEQ ID NO: 7 in Sequence List.
22. (previously presented) A polynucleotide which hybridizes with a polynucleotide according to Claim 20 under a stringent conditions.
23. (previously presented) A recombinant vector comprising a polynucleotide according to Claim 20.
24. (original) The recombinant vector according to Claim 23, wherein the recombinant vector is an expression recombinant vector.
25. (previously presented) A transformant transfected with a recombinant vector according to Claim 23.
26. (previously presented) A method for producing a peptide according to Claim 18, comprising a process for culturing a transformant transfected with an expression recombinant vector comprising a polynucleotide comprising a nucleotide sequence encoding said peptide.
27. (previously presented) An antibody which immunologically recognizes a peptide according to Claim 18.
28. (original) A method of identifying a compound that mediates or inhibits the interaction of a peptide according to Claim 19 with c-Jun N-terminal kinase 3, wherein the method comprises using at least one selected from the peptide, a polynucleotide encoding the peptide, a recombinant vector comprising the polynucleotide, a transformant transfected with the

Preliminary Amendment
U.S. Patent Application No. 10/509,307

recombinant vector, or an antibody which immunologically recognizes the peptide.

29. (original) A method of identifying a compound that mediates or inhibits the expression of a polynucleotide encoding a peptide according to Claim 19, wherein the method comprises using at least one selected from the polynucleotide encoding the peptide, a recombinant vector comprising the polynucleotide, a transformant transfected with the recombinant vector, or an antibody which immunologically recognizes the peptide.

30. (original) A pharmaceutical composition comprising an effective dose of at least one selected from a peptide according to Claim 19, a polynucleotide encoding the peptide, a recombinant vector comprising the polynucleotide, a transformant transfected with the recombinant vector, or an antibody which immunologically recognizes the peptide.

31. (original) An agent for inhibiting the phosphorylation of c-Jun, wherein the agent comprises one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 as the active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List, wherein the peptide is human originated,

(vi) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(vii) a peptide comprising the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xi) a peptide having mutations of one to several amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiii) a peptide having a homology of 70% or more to peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

Preliminary Amendment
U.S. Patent Application No. 10/509,307

32. (original) An agent for inhibiting the ability to activate transcription of c-Jun, wherein the agent comprises one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase-3 as the active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List and human originated,

(vi) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprising the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for

Preliminary Amendment
U.S. Patent Application No. 10/509,307

inhibiting the phosphorylation of c-Jun by JNK3,

(xi) a peptide having mutations of one to several amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiii) a peptide having a homology of 70% or more to peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

33. (original) A pharmaceutical composition comprising an effective dose of an agent for inhibiting the ability to activate transcription of c-Jun according to Claim 32.

34. (original) The pharmaceutical composition according to Claim 33, wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase 3.

35. (original) A pharmaceutical composition comprising an effective dose of one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3), wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3:

(i) BMAL1,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

- (ii) BPL1,
- (iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
- (iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,
- (v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List and human originated,
- (vi) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vii) a peptide comprising the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (viii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (ix) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (x) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (xi) a peptide having mutations of one to several amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(xii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiii) a peptide having a homology of 70% or more to peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

36. (original) A pharmaceutical composition comprising an effective dose of one or more polynucleotides encoding at least one peptide selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase (JNK3), wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun caused by JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 3 in Sequence List and human originated,

(vi) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a

Preliminary Amendment
U.S. Patent Application No. 10/509,307

function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide comprising the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(x) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xi) a peptide having mutations of one to several amino acid residues in an amino acid sequence of the peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiii) a peptide having a homology of 70% or more to peptide of said (v), wherein the peptide is human originated and has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(xiv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(xv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in

Preliminary Amendment
U.S. Patent Application No. 10/509,307

Sequence List.

37. (original) The pharmaceutical composition according to at least one of Claim 34, wherein the disease caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase 3 is a neurodegenerative disease.

38. (original) The pharmaceutical composition according to Claim 37, wherein the neurodegenerative disease is polyglutamine disease, Huntington's disease, spinocerebellar ataxia, bulbosplinal muscular atrophy, dentatorubropallidoluysian atrophy, Alzheimer's disease, Down's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, familial British dementia, Creutzfeldt-Jakob disease, Gerstmann-Stranssler syndrome, mad cow disease (bovine spongiform encephalopathy) (BSE), or familial dementia accompanying neuroserpin inclusion bodies.

39. (original) An agent for inhibiting phosphorylation of c-Jun, wherein the agent comprises one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 as the active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in

Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in

Sequence List,

(v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (1) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

40. (original) A method for inhibiting the phosphorylation of c-Jun, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK3) in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprising at least one of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

41. (original) The method for inhibiting the phosphorylation of c-Jun according to Claim 40, wherein the peptide group consists of (i), (ii), (iii), (iv), (ix), or (x).

42. (original) An agent for inhibiting the ability of c-Jun to activate transcription, wherein the agent comprises one or more than two peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 as the active ingredients:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

43. (original) A method for inhibiting the ability of c-Jun to activate transcription, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase 3 (JNK) in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in

Preliminary Amendment
U.S. Patent Application No. 10/509,307

Sequence List,

(v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

44. (original) A pharmaceutical composition comprising an effective dose of an agent for inhibiting phosphorylation of c-Jun according to Claim 39, or an agent for inhibiting the ability of c-Jun to activate transcription.

45. (original) A pharmaceutical composition according to Claim 44, wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3.

46. (original) A pharmaceutical composition comprising an effective dose of one or more peptides selected from the following peptide group having a function for interacting with c-Jun

Preliminary Amendment
U.S. Patent Application No. 10/509,307

N-terminal kinase (JNK3), wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3:

- (i) BMAL1,
- (ii) BPL1,
- (iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
- (iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,
- (v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or
- (x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

Preliminary Amendment
U.S. Patent Application No. 10/509,307

47. (original) A pharmaceutical composition comprising an effective dose of one or more polynucleotides encoding at least one peptide selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase (JNK3), wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3:

- (i) BMAL1,
- (ii) BPL1,
- (iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,
- (iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,
- (v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,
- (ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

48. (previously presented) The pharmaceutical composition according to Claim 45, wherein the disease caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase is a neurodegenerative disease.

49. (original) The pharmaceutical composition according to Claim 48, wherein the neurodegenerative disease is polyglutamine disease, Huntington's disease, spinocerebellar ataxia, bulbospatial muscular atrophy, dentatorubropallidoluysian atrophy, Alzheimer's disease, Down's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, familial British dementia, Creutzfeldt-Jakob disease, Gerstmann-Strussler syndrome, mad cow disease (bovine spongiform encephalopathy) (BSE), or familial dementia accompanying neuroserpin inclusion bodies.

50. (original) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises putting one or more peptides selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase (JNK3) in coexistence with JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

(iv) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vi) a peptide comprised of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

51. (original) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises utilizing one or more polynucleotides encoding at least one peptide selected from the following peptide group having a function for interacting with c-Jun N-terminal kinase (JNK3) to express the peptide encoded by the polynucleotides, wherein the peptide inhibits the phosphorylation of c-Jun by JNK3:

(i) BMAL1,

(ii) BPL1,

(iii) a peptide composed of the amino acid sequence represented by SEQ ID NO: 1 in Sequence List,

Preliminary Amendment
U.S. Patent Application No. 10/509,307

(iv) a peptide composed of the amino acid sequence represented by SEQ ID NO: 2 in Sequence List,

(v) a peptide comprising at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vi) a peptide composed of at least 5 consecutive amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(vii) a peptide having mutations of one to several amino acid residues in an amino acid sequence of at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(viii) a peptide having a homology of 70% or more to at least one peptide of said (i) to (iv), wherein the peptide has a function for inhibiting the phosphorylation of c-Jun by JNK3,

(ix) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 4 in Sequence List, or

(x) a peptide comprised of the amino acid sequence represented by SEQ ID NO: 5 in Sequence List.

52. (previously presented) A method for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by JNK3, wherein the method comprises using a pharmaceutical composition according to Claim 44.

53. (previously presented) The method for preventing and/or treating disease(s) according to Claim 50, wherein the disease caused by the phosphorylation of c-Jun by c-Jun N-terminal kinase 3 is a neurodegenerative disease.

Preliminary Amendment
U.S. Patent Application No. 10/509,307

54. (original) The method for preventing and/or treating disease(s) according to Claim 53, wherein the neurodegenerative disease is polyglutamine disease, Huntington's disease, spinocerebellar ataxia, bulbofospinal muscular atrophy, dentatorubropallidoluysian atrophy, Alzheimer's disease, Down's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, familial amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, familial British dementia, Creutzfeldt-Jakob disease, Gerstmann-Strassler syndrome, mad cow disease (bovine spongiform encephalopathy) (BSE), or familial dementia accompanying neuroserpin inclusion bodies.

55. (new) A pharmaceutical composition comprising an effective dose of said agent according to Claim 31 for inhibiting the ability to activate transcription of c-Jun.

56. (new) The pharmaceutical composition according to Claim 32, wherein the pharmaceutical composition is an agent for preventing and/or treating disease(s) caused by the phosphorylation of c-Jun by N-terminal kinase 3.